Seminars in Oncology
Volume 29, Issue 3 , Pages 264-273 , June 2002

Prostate-specific antigen in prostate cancer: A case study in the development of a tumor marker to monitor recurrence and assess response

References 

  1. Partin AW, Kattan MW, Subong EN, et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. JAMA. 1997;277:1445–1451
  2. Smith J, Lange P, Jankngt R, et al.  Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate. J Urol. 1997;157:1329–1334
  3. Zietman AL, Dallow KC, McManus PA, et al.  Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease. Urology. 1996;47:236–239
  4. Lee WR, Hanks GE, Hanlon A. Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: Clinical observations. J Clin Oncol. 1996;15:230–238
  5. Greenlee RT, Hill-Harmon MB, Murray T, et al.  Cancer statistics, 2001. CA Cancer J Clin. 2001;51:15–36
  6. Oesterling JE, Jacobsen SJ, Guess HA, et al.  Longitudinal changes in serum PSA (PSA velocity) in a community-based cohort of men. J Urol. 1996;155:595
  7. Partin AW, Kelly CA, Subong EN, et al.  Measurement of the ratio of free PSA to total PSA improves prostate cancer detection for men with total PSA levels between 4.0 and 10.0 ng/ml. Proc Am Urological Assoc. 1995;153:295A; (abstr)
  8. Catalona WJ, Smith DS, Wolfert RL, et al.  Increased specificity of PSA screening through measurement of percent free PSA in serum. Proc AUA. 1995;153:312A; (abstr)
  9. Demura T, Tanaka M, Enami N, et al.  The proportion of free to total prostate specific antigen induced peak in incidence. Utah Cancer Registry. 1996;77:1342–1348
  10. Filella XA, Molina R, Gimenez N, et al.  Clinical usefulness of free PSA fraction as an indicator of prostate cancer. Int J Cancer. 1995;63:780–784
  11. Catalona WJ, Smith DS, Ratliff TL, et al.  Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324:1156–1161
  12. Oesterling JE, Jacobson SJ, Klee GG, et al.  Free, complexed, and total serum prostate specific antigen: The establishment of appropriate reference ranges for the concentrations and ratios. J Urol. 1995;154:1090–1094
  13. Stenman UH, Knekt P, Hakama M, et al.  Serum concentrations of prostate specific antigen and its complex with alpha-1-antichymotrypsin before diagnosis of prostate cancer. Lancet. 1994;344:1594–1598
  14. Catalona W, Smith D, Wolfert R, et al.  Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA. 1995;274:1214–1220
  15. Luderer AA, Chen YT, Soriano TF. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology. 1995;46:187–194
  16. Collins GN, Martin PJ, Wynn-Davies A, et al.  The effect of digital rectal examination, flexible cystoscopy and prostatic biopsy on free and total prostate specific antigen, and the free-to-total prostate specific antigen ratio in clinical practice. J Urol. 1997;157:1744–1747
  17. Adolfsson J, Carstensen J, Lowhagen T. Deferred treatment in clinically localized prostatic carcinoma. Br J Urol. 1992;69:187
  18. Aus G, Hugosson J, Norlen L. Long-term survival and mortality in prostate cancer treated with noncurative intent. J Urol. 1995;154:460–465
  19. Connolly JA, Shinohara K, Presti J, et al.  Local recurrence after radical prostatecotomy: Characteristics in size, location, and relationship to prostate-specific antigen and surgical margins. Urology. 1996;47:225–231
  20. Lange PH, Southwick PC, Catalona WJ, et al.  Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: A prospective multicenter clinical trial. J Urol. 1999;162:1346–1351
  21. Crook JM, Perry GA, Robertson S, et al.  Routine prostate biopsies following radiotherapy for prostate cancer: Results for 226 patients. Urology. 1995;45:624–632
  22. Dugan TC, Shipley WU, Young RH, et al.  Biopsy after external beam radiation therapy for adenocarcinoma of the prostate: Correlation with histological grade and current prostate specific antigen. J Urol. 1991;146:1313–1316
  23. Kuban DA, El-Mahdi AM, Schellhammer P. The significance of post-irradiation prostate biopsy with long-term follow-up. Int J Radiat Oncol Biol Phys. 1992;24:409–414
  24. Schellhammer PF, El-Mahdi AM, Higgins EM, et al.  Prostate biopsy after definitive treatment by interstitial 125-iodine implant or external beam radiation therapy. J Urol. 1987;137:897–901
  25. Partin AW, Pearson JD, Landis PK, et al.  Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology. 1994;43:649–659
  26. Geist RW. Reference range for prostate-specific antigen levels after external beam radiation therapy for adenocarcinoma of the prostate. Urology. 1995;45:1016–1021
  27. Pilepich MV, Krall JM, Al-Sarraf M, et al.  Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group. Urology. 1995;45:616–623
  28. Hanks GE, Schulthesis TE, Hanlon A, et al.  Dose esacalation in the conformal treatment of prostate cancer: Optimization is made possible by understanding the dose responses for control of cancer and late morbidity. Int J Radiat Oncol Biol Physics. 1996;vol 36(suppl 1): abstr
  29. Hanks GE, Buzydlowski JW, Perez CA, et al.  The ten year outcome of pathologic and imaging node positive patients treated with irradiation in Radiation Therapy Oncology Group (RTOG)-7506. J Urol. 1996;155:611A; (suppl, abstr)
  30. Kupelian P, Katcher J, Levin H, et al.  External beam radiotherapy versus radical prostatecomy for clnical stages T1-2 prostate cancer: Therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores. Cancer J Sci Am. 1997;3:78–87
  31. Pisansky TM, Kahn MJ, Rasp GM, et al.  A multiple prognostic index predictive of disease outcome after irradiation for clinically loaclized prostate cancer. Cancer. 1997;79:337–344
  32. Zietman AL, Coen JJ, Shipley WU, et al.  Radical radiation therapy in the management of prostatic adenocarcinoma: The initial prostate specific antigen value as a predictor of treatment outcome. J Urol. 1994;151:640–645
  33. Horwitz E, Ziaja E, Vicini F, et al.  Assessing the variablity of outcome for patients with localized prostate irradiation using different definitions of biochemical failure. Int J Radiat Oncol Biol Phys. 1995;32:228; (suppl, abstr)
  34. ASTRO . Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 1997;37:1035–1041
  35. Taylor JMG, Griffith KA, Sandler HM. Definitions of biochemical failure in prostate cancer following radiation therapy. Int J Radiat Oncol Biol Phys. 2001;50:1212–1219
  36. Hanlon AL, Pinover WH, Horwitz EM, et al.  Patterns and fate of PSA bouncing following 3D-CRT. Int J Radiat Oncol Biol Phys. 2001;50:845–849
  37. Zelefsky MJ, Leibel SA, Wallner KE, et al.  Significance of normal serum prostate-specific antigen in the follow-up period after definitive radiation therapy for prostate cancer. J Clin Oncol. 1995;13:459–463
  38. Kavadi VS, Zagars GK, Pollack A. Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: Prognostic implications. Int J Radiat Oncol Biol Phys. 1994;30:279–287
  39. Tibbs MK, Zietman AL, Dallow KC, et al.  Biochemical outcome following external beam radiation for T1-2 prostate carcinoma: The importance of achieving an undetectable nadir PSA. Int J Radiat Oncol Biol Phys. 1995;32(suppl 1):230; abstr
  40. Doyle K, Weinberg V, Roach M, et al.  What does post-radiotherapy PSA nadir tell us about biochemical failure and progression-free-survival in patients with localized prostate cancer. Proc ASTRO. 2001;2107:279; (abstr)
  41. Nixon RG, Weiner MH, Smith KM, et al.  Biological variation of prostate specific antigen levels in serum: An evaluation of day-to-day physiological fluctuations in a well-defined cohort of 24 patients. J Urol. 1997;157:2183–2190
  42. Takamiya R, Weinberg V, Young CD, et al.  A “zero slope” in post-treatment prostate specific antigen supports “cure” of patients with long-term follow-up after external beam radiation therapy for localized prostate cancer. Proc ASTRO. 2001;2143:298; (abstr)
  43. Leibman BD, Dillioglugil O, Rogers E, et al.  Analyzing PSA trends in recurrent patients after radical prostatectomy and radiotherapy: A novel analysis. J Urol. 1996;155:698A; (suppl, abstr)
  44. Catalona WJ, Smith DS. 5-Year tumor recurrence rates after anatomoical radical prostatectomy for prostate cancer. J Urol. 1994;152:1837–1842
  45. Partin AW, Pound CR, Clemens JQ, et al.  Serum PSA after anatomic radical prostatectomy: The Johns Hopkins experience after 10 years. Urol Clin North Am. 1993;20:713–725
  46. Paulson DF. Impact of radical prostatectomy in the management of clinically localized disease. J Urol. 1994;152:1826–1830
  47. Zincke H, Oesterling JE, Blute ML, et al.  Long-term (15 years) results after radical prostatecomy for clinically localized (staged T2c or lower) prostate cancer. J Urol. 1994;152:1850–1857
  48. Yu H, Diamandis EP, Prestigiacomo AF, et al.  Ultrasensitive assay of prostate-specific antigen used for early detection of prostate cancer relapse and estimation of tumor-doubling time after radical prostatectomy. Clin Chem. 1995;41:430–434
  49. Witherspoon LR, Lapeyrolerie T. Sensitive prostate specific antigen measurements identify men with long disease-free intervals and differentiate aggressive from indolent cancer recurrences within 2 years after radical prostatectomy. J Urol. 1997;157:1322–1328
  50. Stein A, deKernion JB, Smith RB, et al.  Prostate-specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer. J Urol. 1992;147:942–946
  51. Amling CL, Bergstralh EJ, Blute ML, et al.  Defining prostate specific antigen progression after radical prostatectomy: What is the most appropriate cut point?. J Urol. 2001;165:1146–1151
  52. Pound CR, Partin AW, Eisenberger MA, et al.  Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591–1597
  53. Pisansky TM, Kozelsky TF, Myers RP, et al.  Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J Urol. 2000;163:845–850
  54. Leo ME, Bergstralh EJ, Bilhartz DL, et al.  Prostate-specific antigen in hormonally treated stage D2 prostate cancer: Is it always an accurate indicator of disease status?. J Urol. 1991;145:802–806
  55. Miller JI, Drach GW, Ahmann FR, et al.  Clinical usefulness of serum prostate specific antigen after hormonal therapy in metastatic prostate cancer. J Urol. 1992;147:956–961
  56. Matzkin H, Ayalon D, Lewyshon O, et al.  Changes in prostate-specific markers under chronic gonadotropin-releasing hormone analogue treatment of stage D prostatic cancer. Cancer. 1989;63:1287–1291
  57. Stamey TA, Ferrari M, Kabalin JN, et al.  Prostate specific antigen in diagnosis and treatment of adenocarcinoma of prostate. IV. Anti-androgen treated patients. J Urol. 1989;141:1088–1090
  58. Eisenberger M, McLeod D, Hussain M, et al.  Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998;339:1036–1042
  59. Sharifi R, Venner P, Chodak G. Casodex versus castration in treatment of stage D2 prostate cancer: Prostate-specific antigen as a measure of outcome. Proc Am Soc Clin Oncol. 1993;12:241; (abstr)
  60. Scher HI, Kelly W. Flutamide withdrawal syndrome: Its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol. 1993;11:1566–1572
  61. Small EJ, Srinivas S. The antiandrogen withdrawal syndrome: Experience in a large cohort of unselected advanced prostate cancer patients. Cancer. 1995;76:1775–1780
  62. Scher HI, Mazumdar M, Kelly WK. Clinical trials in relapsed prostate cancer: Defining the target. J Natl Cancer Inst. 1996;88:1623–1634
  63. Scher HI, Geller N, Engstrom D, et al.  Trimetrexate in prostatic cancer: Preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease. J Clin Oncol. 1990;8:1830–1838
  64. Kelly WK, Scher HI, Mazumdar M, et al.  Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol. 1993;11:607–615
  65. Smith DC, Dunn RL, Strawderman MS, et al.  Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol. 1998;16:1835–1843
  66. Sridhara R, Eisenberger M, Sinibaldi V, et al.  Evaluation of prostate specific antigen as a surrogate marker for response of hormone refractory prostate cancer to suramin therapy. J Clin Oncol. 1995;13:2944–2953
  67. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol. 1989;1:710–719
  68. Dawson NA. Apples and oranges: Building a consensus for standardized eligibility criteria and end points in prostate cancer clinical trials. J Clin Oncol. 1998;16:3398–3405
  69. Bubley GJ, Carducci M, Dahut W, et al.  Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999;17:3461–3467
  70. Dawson NA, Conoway MR, Halabi S, et al.  A randomized study comparing standard versus moderately high-dose megestrol acetate in advanced prostate cancer: CALGB 9181. Cancer. 2000;88:825–834
  71. Small EJ, McMillan A, Meyer M, et al.  Serum PSA decline as a marker of clinical outcome in hormone refractory prostate cancer patients: Association with progression-free survival, pain endpoints and survival. J Clin Oncol. 2001;19:1304–1310
  72. Tannock I, Gospodarowicz M, Meakin W, et al.  Treatment of metastatic prostate cancer with low-dose prednisone: Evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol. 1989;7:590–597
  73. Thalmann GN, Sikes RA, Chang S-M, et al.  Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer. J Natl Cancer Inst. 1996;88:794–801
  74. Eisenberger MA, Nelson WG. How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution!. J Natl Cancer Inst. 1996;88:779–781
  75. Fossa S, Aaronson N, Newling D. Quality of life and treatment of hormone-resistant metastatic prostate cancer. Eur J Cancer. 1990;26:1133–1136

☆ Address reprint requests to Eric J. Small, MD, University of California San Francisco, 1600 Divisadero St, 3rd Floor, San Francisco, CA

PII: S0093-7754(02)50182-2

doi: 10.1053/sonc.2002.32902

Seminars in Oncology
Volume 29, Issue 3 , Pages 264-273 , June 2002

Article Tools